BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25482936)

  • 1. Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.
    Li S; Wang H; Hong L; Liu W; Huang F; Wang J; Wang P; Zhang X; Zhou J
    Cancer Biol Ther; 2015; 16(1):176-84. PubMed ID: 25482936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
    Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
    J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts.
    Chisamore MJ; Wilkinson HA; Flores O; Chen JD
    Mol Cancer Ther; 2009 Mar; 8(3):672-81. PubMed ID: 19276159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR-3 cells.
    Shi D; Zhao P; Cui L; Li H; Sun L; Niu J; Chen M
    BMC Pharmacol Toxicol; 2020 May; 21(1):32. PubMed ID: 32357920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baicalein has protective effects on the 17β-estradiol-induced transformation of breast epithelial cells.
    Chen Y; Wang J; Hong DY; Chen L; Zhang YY; Xu YN; Pan D; Fu LY; Tao L; Luo H; Shen XC
    Oncotarget; 2017 Feb; 8(6):10470-10484. PubMed ID: 28060756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 8. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway.
    Shi D; Li H; Zhang Z; He Y; Chen M; Sun L; Zhao P
    PLoS One; 2022; 17(1):e0262389. PubMed ID: 35061800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.
    Yao Y; Brodie AM; Davidson NE; Kensler TW; Zhou Q
    Breast Cancer Res Treat; 2010 Nov; 124(2):585-91. PubMed ID: 20623181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
    Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
    J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.
    Ayoub NM; Siddique AB; Ebrahim HY; Mohyeldin MM; El Sayed KA
    Eur J Pharmacol; 2017 Sep; 810():100-111. PubMed ID: 28625568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs).
    Cirillo F; Lappano R; Bruno L; Rizzuti B; Grande F; Guzzi R; Briguori S; Miglietta AM; Nakajima M; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Aug; 38(1):335. PubMed ID: 31370872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
    Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
    Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
    [No Abstract]   [Full Text] [Related]  

  • 19. ERE-independent ERalpha target genes differentially expressed in human breast tumors.
    Glidewell-Kenney C; Weiss J; Lee EJ; Pillai S; Ishikawa T; Ariazi EA; Jameson JL
    Mol Cell Endocrinol; 2005 Dec; 245(1-2):53-9. PubMed ID: 16298037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines.
    Qiu J; Wang X; Guo X; Zhao C; Wu X; Zhang Y
    Oncol Rep; 2009 Oct; 22(4):935-41. PubMed ID: 19724876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.